Pre-Open Stock Movers 05/28: (PHAS) (TGI) (DLTR) (TOL) (ALXN) (HTZ) (TWTR) (More...)

Susquehanna Reiterates Positive Rating on Boeing (BA)

Susquehanna analyst Charles Minervino reiterated a Positive rating and $175.00 price target on Boeing (NYSE: BA). Susquehanna updated its BA model to reflect a more pronounced reduction in 2Q commercial revenues for BGS than previously anticipated, given the significant decline in global air travel this quarter. 2020/2021 EPS estimates... More

Iovance Biotherapeutics (IOVA) Highlights Updated Clinical Data for Tumor Infiltrating Lymphocyte Therapy Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today presented long-term interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma during an oral session at the American Society of Clinical Oncologys (ASCO) ASCO20 Virtual Scientific Program.

We are very pleased to present the long term follow up data for lifileucel in melanoma at the ASCO Scientific Program, said Maria Fardis, Ph.D., President and Chief... More

Dollar Tree (DLTR) PT Raised to $100 at BofA Securities Following 1Q

BofA Securities analyst Robert Ohmes raised the price target on Dollar Tree (NASDAQ: DLTR) to $100.00 (from $86.00) while maintaining a Neutral rating following the company's 1Q earnings report. 1Q EPS of $1.04 was above $0.90 estimates. EBIT margins of 5.8% (vs. 6.6% LY) reflected headwinds from $73.2mn incremental... More

Iovance Biotherapeutics (IOVA) Prices 16.935M Share Common Offering at $31/Sh

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced the pricing of an underwritten public offering of 16,935,484 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $525 million. In... More